Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States

Background: Carfilzomib, an effective proteasome inhibitor agent for the therapy of relapsed and refractory multiple myeloma, has been related to a significant number of cardiovascular events. However, patterns of cardiovascular complications associated with this agent remain poorly characterized in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Yinghong, Ye, Xiaofei, Hu, Fangyuan, Xu, Jinfang, Guo, Xiaojing, Cao, Yang, Lin, Zhen, Zhou, Xiang, Guo, Zhijian, He, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503541/
https://www.ncbi.nlm.nih.gov/pubmed/34646873
http://dx.doi.org/10.3389/fcvm.2021.735466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503541/
https://www.ncbi.nlm.nih.gov/pubmed/34646873
http://dx.doi.org/10.3389/fcvm.2021.735466

Ejemplares similares